Even ‘safe’ levels of antibiotics in food might fuel the next generation of superbugs.
Even tiny traces of antibiotics in the meat and fish we eat could contribute to antibiotic resistance. According to research by the Institute of Tropical Medicine (ITM) in Antwerp, as little as one tenth of the amount of antibiotics currently regarded as ‘safe’ by regulators is enough to trigger resistance in bacteria. Now, the scientists are expanding their research, initially performed on wax moth larvae, to mice and humans.
Our current food system is responsible for around a third of global greenhouse gas emissions, extensive deforestation, unsustainable water usage, and an unprecedented loss of biodiversity. Currently, the processes used to produce our food represent an obstacle to limiting average global temperature increases to the levels set out in the Paris Agreement. But are these damaging effects of our current food production landscape an unavoidable cost of feeding humanity or can smart investments in sustainable agritech be part of the solution?
In a hospital, numerous single-use masks, gloves, syringes, and more are thrown away every day to safeguard patients. However, this linear supply chain leaves a large footprint and can have negative effects on our environment and public health. It seems that the road to achieving sustainable healthcare is not straightforward, but circular.
The adage ‘teamwork makes the dream work’ rings especially true in the dynamic realm of biotech startups. Most successful biotech companies have a foundation built on a robust relationship between their founders and venture capital (VC) partners. This founder-VC partnership represents a symbiotic relationship between a venture capital firm and the founding team of a biotech startup. But what are the key factors for a successful partnership?
An ageing population comes with multiple challenges. Diseases affecting older populations are becoming more prevalent shifting the focus of our healthcare systems. One of the most debilitating is Alzheimer’s disease. Although there is currently no cure, groundbreaking research is expanding our knowledge, giving hope to patients.
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
An estimated 50 million people in Europe regularly go for a run, including almost 20% of the Belgian population. While most might not be running marathons at an Olympic pace, the chance of getting injured can feel inevitable to any runner. This fear is justified, as around half of all runners experience at least one injury annually. But what’s driving this unsettling statistic, and how can runners potentially reduce the likelihood of a dreaded injury spell?
Even ‘safe’ levels of antibiotics in food might fuel the next generation of superbugs.
Even tiny traces of antibiotics in the meat and fish we eat could contribute to antibiotic resistance. According to research by the Institute of Tropical Medicine (ITM) in Antwerp, as little as one tenth of the amount of antibiotics currently regarded as ‘safe’ by regulators is enough to trigger resistance in bacteria. Now, the scientists are expanding their research, initially performed on wax moth larvae, to mice and humans.
Our current food system is responsible for around a third of global greenhouse gas emissions, extensive deforestation, unsustainable water usage, and an unprecedented loss of biodiversity. Currently, the processes used to produce our food represent an obstacle to limiting average global temperature increases to the levels set out in the Paris Agreement. But are these damaging effects of our current food production landscape an unavoidable cost of feeding humanity or can smart investments in sustainable agritech be part of the solution?
In a hospital, numerous single-use masks, gloves, syringes, and more are thrown away every day to safeguard patients. However, this linear supply chain leaves a large footprint and can have negative effects on our environment and public health. It seems that the road to achieving sustainable healthcare is not straightforward, but circular.
The adage ‘teamwork makes the dream work’ rings especially true in the dynamic realm of biotech startups. Most successful biotech companies have a foundation built on a robust relationship between their founders and venture capital (VC) partners. This founder-VC partnership represents a symbiotic relationship between a venture capital firm and the founding team of a biotech startup. But what are the key factors for a successful partnership?
An ageing population comes with multiple challenges. Diseases affecting older populations are becoming more prevalent shifting the focus of our healthcare systems. One of the most debilitating is Alzheimer’s disease. Although there is currently no cure, groundbreaking research is expanding our knowledge, giving hope to patients.
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
An estimated 50 million people in Europe regularly go for a run, including almost 20% of the Belgian population. While most might not be running marathons at an Olympic pace, the chance of getting injured can feel inevitable to any runner. This fear is justified, as around half of all runners experience at least one injury annually. But what’s driving this unsettling statistic, and how can runners potentially reduce the likelihood of a dreaded injury spell?